Relapses in multibacillary patients treated with multi-drug therapy until smear negativity: findings after twenty years

International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association
Gift NormanJoseph Richard

Abstract

The Schieffelin Leprosy Research and Training Center at Karigiri, India participated in several of the World Health Organization (WHO) trials. The first trial on combined therapy in multi-bacillary leprosy was initiated in 1981. The main objectives of this field trial were to evaluate the efficacy of WHO recommended regimens in preventing relapses, especially drug resistance relapses. This paper reports on the relapses twenty years after patients were inducted into the WHO field trial. Between 1981 and 1982, 1067 borderline lepromatous and lepromatous patients were inducted into the WHO field trial for combined therapy in multi-bacillary leprosy trial. Among them, 357 patients were skin smear positive. During the follow-up in 2002, only 173 of them could be traced and assessed. The mean duration of follow-up was 16.4 +/- 1.83 years. Two patients relapsed 14 and 15 years after being released from treatment, the relapse rate being 0.07 per 100 person years follow-up. Drug susceptibility tests done on one of the relapsed patients revealed drug sensitive organisms to all multi-drug therapy drugs.

Citations

Apr 9, 2010·International Ophthalmology Clinics·Sivakumar R Rathinam
Sep 24, 2011·Southern Medical Journal·Mara M DacsoJohn F Prestigiacomo
Apr 15, 2006·Clinical Microbiology Reviews·D M ScollardD L Williams
Dec 25, 2012·Emerging Infectious Diseases·Diana Lynn WilliamsDavid Scollard
Aug 21, 2008·Journal of the European Academy of Dermatology and Venereology : JEADV·S MedeirosM R Vieira
Apr 10, 2008·Tropical Medicine & International Health : TM & IH·Katharina LinderDirk Wagner
Nov 4, 2011·Human Vaccines·Malcolm S DuthieSteven G Reed
Aug 5, 2017·International Journal of Mycobacteriology·Farah NaazUmesh Datta Gupta
Jun 20, 2015·Crisis·Laia Ferrer, Teresa Kirchner
Apr 29, 2020·Autism : the International Journal of Research and Practice·Amanda NitschkeAnne Tm Konkle
Aug 30, 2017·PloS One·Mai Ann BaileyTanya Parish
Oct 9, 2020·PLoS Neglected Tropical Diseases·David M Scollard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.